Search

everythinglearnresearchcommunity

for

Search:↓

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.

Certain genetic variants increase the risk of aggressive prostate cancer.

Baricitinib was effective in treating both early and late onset alopecia areata.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Presurgical models can effectively and affordably screen cancer prevention agents.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Budesonide and N-acetylcysteine reduced tumors and alopecia in mice, regardless of FHIT gene status.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Gefitinib therapy can cause unusual hair growth on the nose.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

EGFR inhibitors can cause unusual localized hair growth.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Nilotinib can cause keratosis pilaris, a skin condition.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.